PMID- 11950380
OWN - NLM
STAT- MEDLINE
DCOM- 20020624
LR  - 20181113
IS  - 1170-7690 (Print)
IS  - 1170-7690 (Linking)
VI  - 20
IP  - 4
DP  - 2002
TI  - Enoxaparin: a pharmacoeconomic review of its use in the prevention and treatment 
      of venous thromboembolism and in acute coronary syndromes.
PG  - 225-43
AB  - The pharmacoeconomics of the low molecular weight heparin (LMWH) enoxaparin in 
      the prophylaxis and treatment of venous thromboembolism have mostly been 
      investigated in cost-effectiveness studies that estimated direct costs associated 
      with treatment, using decision analyses and clinical outcome data from randomised 
      controlled trials. These studies have shown enoxaparin to be cost effective 
      compared with unfractionated heparin (UFH) and warfarin in short-term 
      thromboprophylaxis for hospital inpatients undergoing orthopaedic surgery and in 
      thromboprophylaxis following trauma. Outpatient treatment of acute proximal deep 
      vein thrombosis with enoxaparin has also been shown to be cost effective compared 
      with inpatient treatment using UFH. In general surgery, however, it remains to be 
      determined whether enoxaparin is a cost-effective alternative to UFH. The cost 
      effectiveness of enoxaparin compared with UFH in the treatment of unstable angina 
      and non-Q-wave myocardial infarction has also been investigated in several 
      countries using clinical outcomes data from the Efficacy and Safety of 
      Subcutaneous Enoxaparin in Non-Q-wave Coronary Events (ESSENCE) randomised trial. 
      ESSENCE demonstrated that enoxaparin was superior to UFH in terms of tolerability 
      and efficacy, and cost saving at both 30-day and 1-year follow-ups. An increasing 
      number of studies indicate enoxaparin to be of economic benefit when used for 
      prevention and treatment of venous thromboembolism and treatment of acute 
      coronary symdromes.
FAU - Bergqvist, David
AU  - Bergqvist D
AD  - Department of Surgery, University Hospital, Uppsala, Sweden. 
      david.bergqvist@kirugi.uu.se
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Pharmacoeconomics
JT  - PharmacoEconomics
JID - 9212404
RN  - 0 (Enoxaparin)
RN  - 0 (Fibrinolytic Agents)
MH  - Coronary Disease/*economics/*prevention & control
MH  - Enoxaparin/*economics/*therapeutic use
MH  - Fibrinolytic Agents/*economics/*therapeutic use
MH  - Humans
MH  - Thromboembolism/*economics/*prevention & control
MH  - Venous Thrombosis
EDAT- 2002/04/13 10:00
MHDA- 2002/06/25 10:01
CRDT- 2002/04/13 10:00
PHST- 2002/04/13 10:00 [pubmed]
PHST- 2002/06/25 10:01 [medline]
PHST- 2002/04/13 10:00 [entrez]
AID - 200402 [pii]
AID - 10.2165/00019053-200220040-00002 [doi]
PST - ppublish
SO  - Pharmacoeconomics. 2002;20(4):225-43. doi: 10.2165/00019053-200220040-00002.